IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
ENTHESITIS AND DACTYLITIS

EMERGE TREMFYANT® : Complete resolution of enthesitis at Week 241-5

LEI=Leeds Enthesitis Index; NRI=nonresponder imputation.
*Among patients with LEI enthesitis score >0 at baseline.
Through Week 24, patients were considered to be nonresponders after meeting treatment failure criteria: discontinued study agent for any reason, terminated study participation for any reason, initiated or increased the dose of disease-modifying antirheumatic drugs (DMARDs) or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.
Patients with missing data were considered nonresponders.
§P=0.0301 vs placebo.

||After Week 24, patients and doctors knew that all patients were on TREMFYA® (open label with a blinded dosing interval), which may have affected the results.
The prespecified as-observed analyses at Week 52 and Week 100 are not shown.

Week 24 and Week 52 data are based on DISCOVER 1 and DISCOVER 2 pooled data.

d1-enthesitis100

*Among patients with LEI enthesitis score >0 at baseline.
Patients with missing data were considered nonresponders.
||After Week 24, patients and doctors knew that all patients were on TREMFYA® (open label with a blinded dosing interval), which may have affected the results.
The prespecified as-observed analyses at Week 52 and Week 100 are not shown.

Week 100 data are based on data from the open-label active treatment, NRI post hoc analysis of DISCOVER 2 only.

EMERGE TREMFYANT® : Complete resolution of dactylitis at Week 241-5

NRI=nonresponder imputation.
*Among patients with dactylitis at baseline.
Through Week 24, patients were considered to be nonresponders after meeting treatment failure criteria: discontinued study agent for any reason, terminated study participation for any reason, initiated or increased the dose of disease-modifying antirheumatic drugs (DMARDs) or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.
Patients with missing data were considered nonresponders.
§P=0.0301 vs placebo.

||After Week 24, patients and doctors knew that all patients were on TREMFYA® (open label with a blinded dosing interval), which may have affected the results.
The prespecified as-observed analyses at Week 52 and Week 100 are not shown.

Week 24 and Week 52 data are based on DISCOVER 1 and DISCOVER 2 pooled data.

d2_dactylitis_week100_mobile

*Among patients with dactylitis at baseline.
Patients with missing data were considered nonresponders.
||After Week 24, patients and doctors knew that all patients were on TREMFYA® (open label with a blinded dosing interval), which may have affected the results.
The prespecified as-observed analyses at Week 52 and Week 100 are not shown.

Week 100 data are based on data from the open-label active treatment, NRI post hoc analysis of DISCOVER 2 only.

References: 1. Data on file. Janssen Biotech, Inc. 2. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 3. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126-1136. 4. McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naïve patients with psoriatic arthritis. Arthritis Rheumatol. 2021;73(4):604-616. 5. McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, a monoclonal antibody specific to the p-19 subunit of interleukin-23, through 2 years: results from a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naïve patients with active psoriatic arthritis. Presented at: Innovations in Dermatology 2021; Virtual; March 16-20, 2021.